Disitamab Vedotin Combined With Ivonescimab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

NCT06957561 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Bladder Cancer
Muscle-invasive Bladder Cancer

Interventions

DRUG: Disitamab Vedotin Injection
DRUG: Ivonescimab（AK112，a PD-1/VEGF bispecific antibody）
PROCEDURE: Radical Cystectomy with Pelvic Lymph Node Dissection

Sponsor

Sun Yat-sen University